Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bayer AG is conducting a first-in-human study titled ‘An Open-label, Phase 1, First-in-human, Dose Escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Alpha Inhibitor (DGKαi) BAY 2862789 in Participants With Advanced Solid Tumors.’ The study aims to assess the safety and optimal dosing of BAY2862789, a drug designed to activate T-cells to combat advanced solid tumors, including non-small cell lung cancer.
The intervention being tested is BAY2862789, a drug administered orally in solution or tablet form. It works by inhibiting an enzyme in T-cells, thereby enhancing their anti-cancer activity.
The study is designed as an open-label, single-group assignment with no masking. Its primary purpose is basic science, focusing on understanding the drug’s safety, tolerability, and pharmacokinetics.
The study began on August 7, 2023, with an estimated completion date of July 17, 2025. These dates are crucial as they mark the timeline for data collection and analysis, influencing the drug’s potential market release.
This clinical update could positively impact Bayer’s stock performance by showcasing its commitment to innovative cancer treatments. Investors may view this as a competitive edge in the oncology market, potentially boosting investor sentiment.
The study is currently active and not recruiting, with further details available on the ClinicalTrials portal.